TY - JOUR
T1 - Dual modality imaging of a novel rat model of ovarian carcinogenesis
AU - Kanter, Elizabeth M.
AU - Walker, Ross M.
AU - Marion, Samuel L.
AU - Brewer, Molly
AU - Hoyer, Patricia B.
AU - Barton, Jennifer K.
N1 - Funding Information:
We would like to acknowledge funding from the NIH (AG021948, CA83148, CA109385, and T32 EB00809). We appreciate the helpful conversations with Urs Utzinger and John Davis.
PY - 2006/7
Y1 - 2006/7
N2 - Ovarian cancer is the fifth leading cause of cancer death in women, in part because of the limited knowledge about early stage disease. We develop a novel rat model of ovarian cancer and perform a pilot study to examine the harvested ovaries with complementary optical imaging modalities. Rats are exposed to repeated daily dosing (20 days) with 4-vinylcyclohexene diepoxide (VCD) to cause early ovarian failure (model for postmenopause), and ovaries are directly exposed to 7,12-dimethylbenz(a)anthracene (DMBA) to cause abnormal ovarian proliferation and neoplasia. Harvested ovaries are examined with optical coherence tomography (OCT) and light-induced fluorescence (LIF) at one, three, and five months post-DMBA treatment. VCD causes complete ovarian follicle depletion within 8 months after onset of dosing. DMBA induces abnormal size, cysts, and neoplastic changes. OCT successfully visualizes normal and abnormal structures (e.g., cysts, bursa, follicular remnant degeneration) and the LIF spectra show statistically significant changes in the ratio of average emission intensity at 390:450 nm between VCD-treated ovaries and both normal cycling and neoplastic DMBA-treated ovaries. Overall, this pilot study demonstrates the feasibility of both the novel animal model for ovarian cancer and the ability of optical imaging techniques to visualize ovarian function and health.
AB - Ovarian cancer is the fifth leading cause of cancer death in women, in part because of the limited knowledge about early stage disease. We develop a novel rat model of ovarian cancer and perform a pilot study to examine the harvested ovaries with complementary optical imaging modalities. Rats are exposed to repeated daily dosing (20 days) with 4-vinylcyclohexene diepoxide (VCD) to cause early ovarian failure (model for postmenopause), and ovaries are directly exposed to 7,12-dimethylbenz(a)anthracene (DMBA) to cause abnormal ovarian proliferation and neoplasia. Harvested ovaries are examined with optical coherence tomography (OCT) and light-induced fluorescence (LIF) at one, three, and five months post-DMBA treatment. VCD causes complete ovarian follicle depletion within 8 months after onset of dosing. DMBA induces abnormal size, cysts, and neoplastic changes. OCT successfully visualizes normal and abnormal structures (e.g., cysts, bursa, follicular remnant degeneration) and the LIF spectra show statistically significant changes in the ratio of average emission intensity at 390:450 nm between VCD-treated ovaries and both normal cycling and neoplastic DMBA-treated ovaries. Overall, this pilot study demonstrates the feasibility of both the novel animal model for ovarian cancer and the ability of optical imaging techniques to visualize ovarian function and health.
KW - 4-vinylcyclohexene diepoxide
KW - 7,12-dimethylbenz(a) anthracene
KW - Light-induced fluorescence
KW - Menopause
KW - Optical coherence tomography
KW - Ovarian cancer
UR - http://www.scopus.com/inward/record.url?scp=33751321431&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33751321431&partnerID=8YFLogxK
U2 - 10.1117/1.2236298
DO - 10.1117/1.2236298
M3 - Article
C2 - 16965151
AN - SCOPUS:33751321431
SN - 1083-3668
VL - 11
JO - Journal of biomedical optics
JF - Journal of biomedical optics
IS - 4
M1 - 041123
ER -